Toggle Main Menu Toggle Search

Open Access padlockePrints

An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome

Lookup NU author(s): Emeritus Professor Nick Europe-Finner


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Bronchiolitis obliterans syndrome (BUS) is a major complication of lung transplantation that is associated with poor survival. The International Society for Heart and Lung Transplantation, American Thoracic Society, and European Respiratory Society convened a committee of international experts to describe and/or provide recommendations for 1) the definition of BUS, 2) the risk factors for developing BUS, 3) the diagnosis of BUS, and 4) the management and prevention of BUS.A pragmatic evidence synthesis was performed to identify all unique citations related to BUS published from 1980 through to March, 2013. The expert committee discussed the available research evidence upon which the updated definition of BUS, identified risk factors and recommendations are based. The committee followed the GRADE (Grading of Recommendation, Assessment, Development and Evaluation) approach to develop specific clinical recommendations.The term BOS should be used to describe a delayed allograft dysfunction with persistent decline in forced expiratory volume in 1 s that is not caused by other known and potentially reversible causes of post-transplant loss of lung function. The committee formulated specific recommendations about the use of systemic corticosteroids, cyclosporine, tacrolimus, azithromycin and about re-transplantation in patients with suspected and confirmed BUS.The diagnosis of BUS requires the careful exclusion of other post-transplant complications that can cause delayed lung allograft dysfunction, and several risk factors have been identified that have a significant association with the onset of BUS. Currently available therapies have not been proven to result in significant benefit in the prevention or treatment of BUS. Adequately designed and executed randomised controlled trials that properly measure and report all patient-important outcomes are needed to identify optimal therapies for established BUS and effective strategies for its prevention.

Publication metadata

Author(s): Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, Brozek J, Glanville AR, ISHLT ATS ERS BOS Task Force Comm

Publication type: Review

Publication status: Published

Journal: European Respiratory Journal

Year: 2014

Volume: 44

Issue: 6

Pages: 1479-1503

Print publication date: 01/12/2014

Online publication date: 30/10/2014

Acceptance date: 26/08/2014

ISSN (print): 0903-1936

ISSN (electronic): 1399-3003



DOI: 10.1183/09031936.00107514